TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34529811

Group type: EXPERIMENTAL
Intervention: Caffeinated gum (4 mg/kg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 36086732

Group type: EXPERIMENTAL
Intervention: Married patients
Number of subjects: 5477

Group type: EXPERIMENTAL
Intervention: Single/unmarried patients
Number of subjects: 5477

Group type: EXPERIMENTAL
Intervention: Separated/widowed/divorced patients
Number of subjects: 5477
Study: 35255814

Group type: EXPERIMENTAL
Intervention: Near point-of-care CT and NG testing and treatment intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antenatal care (WHO-endorsed syndromic management)
Number of subjects: 0
Study: 34068577

Group type: EXPERIMENTAL
Intervention: Brochure with six short photo stories
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Non-narrative brochure with comparable photos
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Traditional brochure
Number of subjects: 471

Group type: COMPARATOR
Intervention: All brochure versions
Number of subjects: 471
Study: 32658797

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus ropivacaine (1 μg kg−1 dexmedetomidine and 0.25% ropivacaine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ropivacaine alone (0.25% ropivacaine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus ropivacaine
Number of subjects: 120
Study: 35555278

Group type: EXPERIMENTAL
Intervention: HMB+D (3g of HMB + 2000IU of Vitamin D3)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 33148538

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37756542

Group type: EXPERIMENTAL
Intervention: Insulin glargine U-100
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 5047
Study: 33451627

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1000 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Oral acetaminophen (1000 mg)
Number of subjects: 121
Study: 34748929

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 402
Study: 32046665

Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Upfront combination therapy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Monitoring HER2ECD levels
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: HER2ECD baseline levels
Number of subjects: 133
Study: 35130964

Group type: EXPERIMENTAL
Intervention: Preparing for Sustainment (PS)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sustainment as Usual (SAU)
Number of subjects: 360
Study: 34142483

Group type: EXPERIMENTAL
Intervention: Drowning cases (31)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Non-drowning cases (123)
Number of subjects: 154
Study: 34863879

Group type: EXPERIMENTAL
Intervention: Zataria multiflora 5 mg/kg/day (Z5)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Zataria multiflora 10 mg/kg/day (Z10)
Number of subjects: 36
Study: 35112475

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (3 grams per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Number of subjects: 40
Study: 34678860

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 35235834

Group type: EXPERIMENTAL
Intervention: mHealth intervention with just-in-time adaptive intervention (JITAI) promoting low-level physical activity and exercise, including access to activity tracking and goal setting through a mobile application, and weekly activity summaries via email.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care with a compatible smartwatch (Fitbit Versa 2 or Apple Watch 4).
Number of subjects: 0
Study: 33202916

Group type: EXPERIMENTAL
Intervention: fiber‐focused point‐of‐decision prompt (PDP)
Number of subjects: 753

Group type: COMPARATOR
Intervention: no‐PDP condition (control)
Number of subjects: 753
Study: 33608239

Group type: EXPERIMENTAL
Intervention: COBRA PzF stent followed by very short duration (14 days) DAPT
Number of subjects: 996

Group type: COMPARATOR
Intervention: FDA-approved new generation drug-eluting stent followed by guideline-recommended DAPT duration (3 or 6 months)
Number of subjects: 996
Study: 34034268

Group type: EXPERIMENTAL
Intervention: Midodrine (15 mg daily) and albumin (20 g weekly) in group‐A (Gp‐A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Albumin (20 g weekly) alone in group‐B (Gp‐B)
Number of subjects: 42
Study: 36050743

Group type: EXPERIMENTAL
Intervention: Multifaceted strategy (implementation teams, educational meeting, ongoing training, Plan-Do-Study-Act cycles)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Single strategy (implementation teams, educational meeting)
Number of subjects: 55
Study: 34516489

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral active engagement training
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 148
Study: 33872448

Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics with mechanical bowel preparation (MBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative oral antibiotics without mechanical bowel preparation (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics with MBP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative oral antibiotics without MBP (control)
Number of subjects: 0
Study: 33057642

Group type: EXPERIMENTAL
Intervention: Prehospital plasma administration (2 units of thawed plasma)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Prehospital plasma administration
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard care resuscitation
Number of subjects: 166
Study: 35505620

Group type: EXPERIMENTAL
Intervention: Contextual behavioural intervention (3 sessions of 1 hour each)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 94
Study: 33352600

Group type: EXPERIMENTAL
Intervention: Marine phytoplankton supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marine phytoplankton 2.55 mg·d‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marine phytoplankton 5.1 mg·d‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study: 32281081

Group type: EXPERIMENTAL
Intervention: Lower extremity exercise intervention (50 minutes, three times a week for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study: 34255042

Group type: EXPERIMENTAL
Intervention: Estradiol levels (high)
Number of subjects: 311675
Study: 32697559

Group type: EXPERIMENTAL
Intervention: Toric contact lenses
Number of subjects: 35

Group type: COMPARATOR
Intervention: Spherical contact lenses
Number of subjects: 35
Study: 36282295

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 28008

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28008
Study: 34744149

Group type: EXPERIMENTAL
Intervention: Ivabradine (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (20 mg)
Number of subjects: 0
Study: 35460392

Group type: EXPERIMENTAL
Intervention: AMG 986 (up to 650 mg/day)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: AMG 986
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 33653320

Group type: EXPERIMENTAL
Intervention: Serratiopeptidase
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Paracetamol + Serratiopeptidase
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo + Paracetamol
Number of subjects: 133
Study: 32106714

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 38
Study: 34075419

Group type: EXPERIMENTAL
Intervention: Corticosteroids (RCTs)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Various interventions (non-randomized studies)
Number of subjects: 133
Study: 32989543

Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 91

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 91
Study: 36088057

Group type: EXPERIMENTAL
Intervention: Prolutex (25 mg daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Crinone (90 mg daily)
Number of subjects: 65
Study: 33874917

Group type: EXPERIMENTAL
Intervention: Web-based aftercare (digIRENA)
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Traditional face-to-face aftercare (IRENA)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1150
Study: 35608457

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 42
Study: 34023219

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 485
Study: 32062671

Group type: EXPERIMENTAL
Intervention: Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab combination therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cetuximab as an alternative treatment
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cetuximab treatment for ≥10 months
Number of subjects: 96
Study: 33123978

Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 149

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 149
Study: 35569811

Group type: EXPERIMENTAL
Intervention: AirSeal insufflation system with pneumoperitoneum between 8 and 10 mm Hg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard insufflation system with pneumoperitoneum between 12 and 15 mm Hg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AirSeal insufflation system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard insufflation system
Number of subjects: 80
Study: 33990437

Group type: EXPERIMENTAL
Intervention: Preoperative parasternal plane block (PSB) using ropivacaine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline solution (placebo group)
Number of subjects: 35
Study: 33152467

Group type: EXPERIMENTAL
Intervention: BGF MDI 320/18/9.6 μg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: BGF MDI 160/18/9.6 μg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: BGF MDI (both doses)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: BGF MDI
Number of subjects: 264
Study: 35871718

Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) oil supplementation (2 g/daily for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 60
Study: 33341916

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Minimally invasive pancreatoduodenectomy (MIPD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Laparoscopic pancreatoduodenectomy (MIPD)
Number of subjects: 5
Study: 32197620

Group type: EXPERIMENTAL
Intervention: CHF6001 800 μg BID
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CHF6001 1600 μg BID
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 34000754

Group type: EXPERIMENTAL
Intervention: Robotic arm-assisted THA
Number of subjects: 99
Study: 32561266

Group type: EXPERIMENTAL
Intervention: HTX-011 400 mg bupivacaine/12 mg meloxicam
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: HTX-011 400 mg bupivacaine/12 mg meloxicam with 50 mg ropivacaine
Number of subjects: 232

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride (HCl) 125 mg injection
Number of subjects: 232

Group type: COMPARATOR
Intervention: Saline placebo injection
Number of subjects: 232
Study: 32889881

Group type: EXPERIMENTAL
Intervention: Novel Oral Anticoagulant (NOAC) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 32132845

Group type: EXPERIMENTAL
Intervention: Flywheel eccentric overload group (FEO)
Number of subjects: 34
Study: 34309740

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training combined with dual tasks (PFMT‐DT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (physical training only)
Number of subjects: 88
Study: 33285008

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (15 IU.kg−1 based on factor IX)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fresh frozen plasma (15 ml.kg−1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fresh frozen plasma
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate and fresh frozen plasma
Number of subjects: 50
Study: 34500234

Group type: EXPERIMENTAL
Intervention: Binary disease model beliefs with stigmatising language
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Continuum beliefs
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 244
Study: 33378750

Group type: EXPERIMENTAL
Intervention: CHL-PRED
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CHL
Number of subjects: 69

Group type: COMPARATOR
Intervention: AQUA
Number of subjects: 69
Study: 35293367

Group type: EXPERIMENTAL
Intervention: Work participation after 1 year
Number of subjects: 116
Study: 33554745

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) with demonstrations and pictorial instructions
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 637
Study: 32527676

Group type: EXPERIMENTAL
Intervention: Virtual reality based cognitive behavioral therapy (VR‐CBT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 91
Study: 34806929

Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 2
Study: 33839552

Group type: EXPERIMENTAL
Intervention: Aromatherapy (inhalation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aromatherapy (massage)
Number of subjects: 16
Study: 35253448

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (450 mg/d)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (450 mg/d)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (450 mg/d)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 32173961

Group type: EXPERIMENTAL
Intervention: Leukocyte subsets (neutrophils, lymphocytes, monocytes, basophils) in men with AAA
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Neutrophils
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Lymphocytes
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Monocytes
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Neutrophils and lymphocytes
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (AAA-free men)
Number of subjects: 375
Study: 616063536

Group type: EXPERIMENTAL
Intervention: Veliparib/Carboplatin (VC)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 116
Study: 35218628

Group type: EXPERIMENTAL
Intervention: Pinggan Jiangya decoction combined with penetrating needling at Baihui (GV20) once daily for 8 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Pinggan Jiangya decoction once daily for 8 weeks
Number of subjects: 150
Study: 33096497

Group type: EXPERIMENTAL
Intervention: Nurse-trained, family member-delivered rehabilitation model
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 61
Study: 36468948

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (general rehabilitation programs)
Number of subjects: 100
Study: 33418362

Group type: EXPERIMENTAL
Intervention: CADSS-6 (6-item version of the Clinician-Administered Dissociative States Scale)
Number of subjects: 260
Study: 33415915

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as add-on treatment
Number of subjects: 120
Study: 35739551

Group type: EXPERIMENTAL
Intervention: E-SEE Steps intervention
Number of subjects: 339
Study: 33751652

Group type: EXPERIMENTAL
Intervention: Personal oral hygiene (pOH) at daily intervals (12-24 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Personal oral hygiene (pOH) at extended intervals (48 hours)
Number of subjects: 42
Study: 32012323

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - school-based intervention for increasing physical activity and reducing sedentary time
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - school-based intervention
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control Group (CG) - no intervention
Number of subjects: 597
Study: 34429224

Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone with particulate acemannan (mean size 32.45 μm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Deproteinized bovine bone only
Number of subjects: 20
Study: 35124915

Group type: EXPERIMENTAL
Intervention: Intralesional vitamin D3
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 50
Study: 35244717

Group type: EXPERIMENTAL
Intervention: Kisspeptin administration
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 33288408

Group type: COMPARATOR
Intervention: Single vision silicone hydrogel contact lenses (control lens)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Two anti-myopia silicone hydrogel contact lenses (test lens I and II)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Two extended depth of focus hydrogel contact lenses (test lens III and IV)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Non-adherent wearers (all lens types)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Factors associated with non-adherence
Number of subjects: 379
Study: 33197941

Group type: EXPERIMENTAL
Intervention: 19G Flex needle
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 22G needle
Number of subjects: 250

Group type: COMPARATOR
Intervention: 19G needle
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: All needles
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cyst aspirate diagnostic accuracy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 250
Study: 32553888

Group type: EXPERIMENTAL
Intervention: Hyperoxic HIIT (HHIIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxic HIIT (NHIIT)
Number of subjects: 16
Study: 36150995

Group type: EXPERIMENTAL
Intervention: Echocardiogram parameters used for predicting surgery eligibility
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Scoring system based on echocardiogram parameters
Number of subjects: 1785
Study: 32663928

Group type: EXPERIMENTAL
Intervention: Newly derived Hamilton depression scale measures (9-item and 4-item scales)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Total Hamilton depression measure
Number of subjects: 5
Study: 34737211

Group type: EXPERIMENTAL
Intervention: FBXW7 knockout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FBXW7 deletion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FBXW7 deficiency
Number of subjects: 0
Study: 34949098

Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) for coronary heart disease (CHD)
Number of subjects: 12792

Group type: COMPARATOR
Intervention: Conventional risk factors
Number of subjects: 12792

Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) added to conventional risk factors
Number of subjects: 12792
Study: 32330775

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 39
Study: 32459394

Group type: EXPERIMENTAL
Intervention: Sun Safety Schools (SSS) intervention
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Parents receiving sun safety information
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 118
Study: 35773604

Group type: EXPERIMENTAL
Intervention: ERAS+ group (guideline-based ERAS protocol)
Number of subjects: 118

Group type: COMPARATOR
Intervention: ERAS- group (standard care)
Number of subjects: 118
Study: 34506358

Group type: EXPERIMENTAL
Intervention: Daily mobile reporting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Daily swabbing arm
Number of subjects: 30

Group type: COMPARATOR
Intervention: YSTR mixtures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Detection of HIV‐1 total nucleic acids
Number of subjects: 30
Study: 33212256

Group type: EXPERIMENTAL
Intervention: Favipiravir (1800 mg BID on day 1 and 800 mg BID from days 2-14) plus standard supportive care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (supportive care alone)
Number of subjects: 150
Study: 35086209

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Number of subjects: 470

Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 470

Group type: COMPARATOR
Intervention: NSAIDs (including nepafenac 0.1%, bromfenac 0.07%, preservative-free ketorolac 0.4%, nepafenac 0.3%)
Number of subjects: 470
Study: 36462528

Group type: EXPERIMENTAL
Intervention: Single low-dose primaquine combined with artemether-lumefantrine
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Single low-dose primaquine combined with dihydroartemisinin-piperaquine
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Placebo combined with artemether-lumefantrine
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Placebo combined with dihydroartemisinin-piperaquine
Number of subjects: 1137
Study: 35639381

Group type: EXPERIMENTAL
Intervention: Mailed educational materials to patients and/or clinicians
Number of subjects: 47333

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 47333
Study: 36195683

Group type: EXPERIMENTAL
Intervention: Hypercaloric diet (25% increase of energy intake by fat)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normocaloric diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Number of subjects: 20
Study: 33752738

Group type: EXPERIMENTAL
Intervention: Intervention from the LipiDiDiet study
Number of subjects: 0
Study: 33339438

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients, lutein, and docosahexaenoic acid (DHA) supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70